Teva Pharmaceutical Industries (NYSE: TEVA) is set to report its second-quarter results on Wednesday, July 30, 2026, before the market opens. The report is expected to show a significant divergence between underlying operational strength and reported earnings, primarily due to a $700 million charge related to the Emalex acquisition.
Wall Street consensus, as compiled by Virtua Research, projects revenue of $4.058 billion and non-GAAP earnings per share of $0.59, excluding the Emalex impact. However, after accounting for the acquisition-related expense of approximately $0.59 per share, the reported non-GAAP EPS is expected to be near zero, with estimates ranging from a loss of $0.03 to a profit of $0.13 per share.
Teva's stock closed at $30.81 on Friday, down 3.8% for the week. The company's market valuation now reflects a forward P/E of 15.3 times the midpoint of its 2026 guidance, which drops to 11.5 times when using Teva's own independent outlook. Analysts remain largely bullish, with 13 out of 13 covering analysts rating the stock as Buy or Overweight and a consensus price target of $41.75, implying a 35.5% upside from Friday's close.
Sequential Progress Expected
Teva's management has emphasized a strategy of incremental quarterly improvements, and the Q2 consensus supports this narrative. Revenue is forecast to rise 1.9% sequentially to $4.058 billion, while free cash flow is expected to nearly double to $367 million from $188 million in Q1. Non-GAAP EPS is projected to increase 11.3% from $0.53 to $0.59 before the Emalex charge.
The company's three growth brands—Austedo, Ajovy, and Uzedy—collectively generated $837 million in Q1 revenue. For Q2, the consensus estimate is $843 million, a modest 0.7% increase. Austedo sales are expected to grow 1.7% to $588 million, Ajovy to decline 4.6% to $187 million, and Uzedy to rise 7.9% to $68 million. To meet the full-year midpoint of $3.51 billion for these brands, the average quarterly revenue in the second half would need to reach approximately $915 million, representing an 8.5% jump from the Q2 consensus.
JPMorgan analyst Chris Schott described Teva's core assets as "growing nicely" after the first quarter and noted an "attractive setup for shares" as growth is expected to accelerate after 2026.
Generics Headwinds and Tariff Risk
Branded-drug growth is critical to offset a steep decline in Teva's generics business. Global generics sales dropped 16% in constant currency in Q1, and the company expects to lose over $1 billion in revenue from lenalidomide this year. A new policy risk emerged last week when President Donald Trump announced that imported generics will face no tariffs for two years, but rates will climb to 100% in 2028 and 200% thereafter. Sandoz Group stated the proposal lacks sufficient detail, while Teva has previously highlighted its U.S., Israeli, and European operations as providing greater protection.
Cash Flow and Debt Concerns
Cash conversion remains a key focus. Teva faces $1.798 billion in notes maturing on October 1, 2026, and anticipates $379 million in opioid settlement payments for the full year. Strong free cash flow generation is essential to manage these obligations and maintain financial flexibility.
Teva will report results at 7:00 a.m. ET on Wednesday, followed by a conference call at 8:00 a.m. ET. Analysts will be closely watching combined branded sales of $843 million as a more reliable indicator of underlying performance than the distorted EPS figure.
